<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Consensus treatment recommendations for late-onset Pompe disease.&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT, AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012 Mar;45(3):319-33. [108 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22173792&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="HCPCS: Cane, includes canes of all materials, adjustable or fixed, with tip ; Continuous positive airway pressure (cpap) device "/><FieldValue Value="ICD9CM: Esophageal reflux  (530.81); General physical examination  (89.7); Glycogenosis  (271.0); Osteoporosis, unspecified  (733.00)"/><FieldValue Value="MSH: Absorptiometry, Photon ; Accidental Falls ; alpha-Glucosidases ; Anti-Asthmatic Agents ; Anti-Bacterial Agents ; Antiviral Agents ; Asthma ; Calcium, Dietary ; Canes ; Cardiomyopathies ; Continuous Positive Airway Pressure ; Contracture ; Diphosphonates ; Enzyme Replacement Therapy ; Exercise ; Exercise Therapy ; Gastroesophageal Reflux ; Glycogen Storage Disease ; Glycogen Storage Disease Type II ; Growth and Development ; Influenza Vaccines ; Medication Therapy Management ; Minerals ; Neonatal Screening ; Nutrition Therapy ; Nutritionists ; Orthopedic Procedures ; Orthotic Devices ; Osteoporosis ; Patient Care Team ; Patient Education as Topic ; Physical Examination ; Pneumococcal Vaccines ; Respiratory Therapy ; Self-Help Devices ; Serologic Tests ; Suction ; Vitamin D ; Vitamins ; Walkers "/><FieldValue Value="MTH: Accidental Falls ; Alpha-glucosidase ; Anti-Bacterial Agents ; Antiviral Agents ; Asthma ; Calcium, Dietary ; CANE, INCLUDES CANES OF ALL MATERIALS, ADJUSTABLE OR FIXED, WITH TIP ; Cardiomyopathies ; Continuous Positive Airway Pressure ; Contracture ; Diphosphonates ; Endocrinologist review ; Exercise ; Fall risk assessment ; follow-up ; Gastroesophageal reflux disease ; Glycogen storage disease type II ; Growth and Development function ; Influenza virus vaccine ; Minerals ; Nutrition Therapy ; Nutritionist ; Orthotic Devices ; Osteoporosis ; Patient education (procedure) ; physical examination ; Physical therapy exercises ; Pneumococcal vaccine ; Respiratory airway clearance ; Respiratory Therapy ; Serologic tests ; Suction drainage ; Vitamin D ; Vitamins "/><FieldValue Value="PDQ: osteoporosis "/><FieldValue Value="SNOMEDCT_US: Accidental fall  (217082002); Alpha glucosidase  (16783009); Alpha glucosidase  (398923002); Antiasthmatic agent  (360253007); Antibacterial agent  (346325008); Antibacterial agent  (419241000); Antiviral agent  (32249005); Antiviral agent  (372701006); Assessment of sense of balance  (427226009); Assistive equipment  (360296002); Asthma  (195967001); At risk for falls  (129839007); At risk of osteoporosis  (313423004); Cardiologist  (17561000); Cardiomyopathy  (57809008); Cardiomyopathy  (85898001); Cardiovascular physical examination  (363003006); Continuing positive airway pressure unit  (37874008); Continuous positive airway pressure ventilation treatment  (47545007); Contracture  (55033002); Contracture  (57048009); Diphosphonate  (372907000); Diphosphonate  (96281001); Examination of respiratory system  (268925001); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Fall risk assessment  (414191008); Gait training procedure  (74914000); Gastroesophageal reflux disease  (235595009); Gastroesophageal reflux disease  (698065002); Generalized glycogenosis  (124454007); Generalized glycogenosis  (124462004); Generalized glycogenosis  (237967002); Generalized glycogenosis  (267424007); Glycogen storage disease  (29633007); Increased protein diet  (14627000); Increased protein diet  (437461000124104); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Inspiratory muscle training  (229300005); Mineral  (87918000); Neonatal screening  (60151004); Nutrition therapy  (386373004); Orthotic device  (224898003); Osteoporosis  (64859006); Patient education  (311401005); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Pulmonologist  (41672002); Respiratory therapy  (53950000); Serologic test  (68793005); Suction drainage  (274441001); Therapeutic exercise  (226029000); Therapeutic exercise  (229065009); Therapeutic exercise  (51998003); Videofluoroscopy swallow  (241149003); Vitamin  (12968008); Vitamin  (87708000); Vitamin D  (11563006); Vitamin D  (30178006); Walker  (49338004); Walker  (705406009); Walking stick  (360006004); Walking stick  (87405001)"/><FieldValue Value="SPN: CANE, SAFETY WALK "/><FieldValue Value="UMD: Airway Clearance Units  (18-863); Canes  (10-560); Orthoses  (12-837); Positive Airway Pressure Units, Bi-Level  (20-743); Positive Airway Pressure Units, Continuous  (11-001); Walkers  (14-393)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Late-onset Pompe disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Rehabilitation" /><FieldValue Value="Risk Assessment" /><FieldValue Value="Screening" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Cardiology" /><FieldValue Value="Endocrinology" /><FieldValue Value="Family Practice" /><FieldValue Value="Gastroenterology" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Medical Genetics" /><FieldValue Value="Neurology" /><FieldValue Value="Nutrition" /><FieldValue Value="Pediatrics" /><FieldValue Value="Physical Medicine and Rehabilitation" /><FieldValue Value="Pulmonary Medicine" /><FieldValue Value="Sleep Medicine" /><FieldValue Value="Speech-Language Pathology" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Dietitians" /><FieldValue Value="Nurses" /><FieldValue Value="Occupational Therapists" /><FieldValue Value="Physical Therapists" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /><FieldValue Value="Social Workers" /><FieldValue Value="Speech-Language Pathologists" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;To propose consensus-based treatment and&#xA;management recommendations for late-onset Pompe disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with late-onset Pompe disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;Musculoskeletal element of late-onset Pompe disease&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Providing patients with information on resources related to late-onset Pompe disease &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Physical examination and assessments&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Examination by a cardiologist and pulmonologist before beginning an exercise program &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Screening with dual-energy x-ray absorptiometry (DEXA) with yearly follow-ups &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Medical evaluation, laboratory testing, and medication review by an endocrinologist or bone density specialist &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Fall risk assessment, formal evaluation for balance, and safe gait training for patients at increased risk for osteoporosis and falls &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Adaptive equipment, such as a cane or walker &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Exercise program developed by a physical or occupational therapist &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Management of contractures (orthotic devices, surgical interventions) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Vitamin D, calcium, and bisphosphonate supplements &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Respiratory element of late-onset Pompe disease&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Management by pulmonologist experienced with neuromuscular diseases &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Up-to-date vaccinations, including vaccination against pneumococcus and influenza &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Early and aggressive treatment of bacterial and viral infections &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Clearing secretions from airways (e.g., cough assist device, suction) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Training/educating patients and families to use assisted cough and inspiratory muscle techniques &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Treatment of sleep-disordered breathing with continuous positive airway pressure (CPAP) or bilevel nocturnal noninvasive ventilation (BiPAP) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Treatment of concomitant conditions, such as asthma or cardiomyopathy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Enzyme replacement therapy (ERT) (alglucosidase alfa [Lumizyme])&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Initiation of ERT based on symptom assessment &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Duration of ERT &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Monitoring ERT for effectiveness and immunoglobulin G (IgG) antibodies &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Gastrointestinal element of late-onset Pompe disease&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Coordinating treatment through a multidisciplinary neuromuscular clinic &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Involving an experienced dietitian in management &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Videofluoroscopic swallowing assessment and evaluation for gastroesophageal reflux &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring growth parameters &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Providing adequate nutrition consisting of high protein diet, vitamins and minerals &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Educating patients about the appropriate use of over-the-counter medications &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Monitoring for IgG antibodies in patients receiving ERT &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementation of newborn screening programs &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary function &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Muscle strength &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Distance walked during a 6-minute walk test &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Percent of predicted forced vital capacity (FVC) in the upright position &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Hand-searches of Published Literature (Primary Sources)" /><FieldValue Value="Hand-searches of Published Literature (Secondary Sources)" /><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A literature search was conducted in the PubMed and EMBASE databases for clinical trials and relevant articles published before June 2010. The search terms included &lt;em&gt;Pompe disease, acid alpha-glucosidase deficiency, acid maltase deficiency, glycogen storage disease type II&lt;/em&gt;, and &lt;em&gt;glycogenosis type II&lt;/em&gt;. Panel members reviewed these articles individually and discussed them in small group sessions. Subsequently, the panel convened for further discussion and consensus development. In addition, articles published after the consensus meeting was held, references cited by the articles produced by the literature search, and references suggested by the authors are included in this article.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The literature search produced 105 articles relevant to Pompe disease.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus (Consensus Development Conference)" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) convened a consensus committee of specialists with expertise in the diagnosis and treatment of Pompe disease. The AANEM consensus panel, consisting of several neuromuscular specialists and a pulmonologist, reviewed all articles found as a result of the literature search. Each panel member was assigned a section to write and review. Using a modified consensus development conference method, the committee worked to create consensus-based recommendations for the treatment of late-onset Pompe disease.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A formal cost analysis was not performed and published cost analyses were not reviewed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline underwent peer review by the Professional Practice Committee and the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Board.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline was approved by the AANEM Board, September 2011.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment Recommendations for the Musculoskeletal Element of Late-Onset Pompe Disease&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Provide Patient with Information on the Following Resources&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Muscular Dystrophy Association &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acid Maltase Deficiency Association &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pompe Registry &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Association for Glycogen Storage Disease &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;International Pompe Association &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Physical Examination and Assessments&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients should be examined by a cardiologist and pulmonologist before beginning an exercise program. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Screen all patients diagnosed with Pompe disease, regardless of age and wheelchair use, with dual-energy x-ray absorptiometry (DEXA); follow-ups can be considered on a yearly basis. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with late-onset Pompe disease and reduced bone density should undergo medical evaluation, including laboratory testing and medication review by an endocrinologist or bone density specialist. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Conduct fall risk assessment followed by a formal evaluation for balance and safe gait training for patients at increased risk for osteoporosis and falls. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommend adaptive equipment, such as a cane or walker, to reduce risk of falls. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Physical/Occupational Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A physical or occupational therapist should develop an exercise program that may include one or more of the following: walking, treadmill, cycling, pool-based program, swimming, submaximal aerobic exercise, or muscle strengthening, that follows the guidelines for other degenerative muscle diseases. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Avoid overwork weakness, excessive fatigue, disuse, strenuous exercises, and eccentric contractions. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Emphasize submaximal aerobic exercise. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Incorporate functional activities when possible. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Teach patient to monitor heart rate and breathing in relation to exertion. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Integrate energy conservation techniques and biomechanical advantages. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;A preventive stretching regimen should be started early and performed as part of the daily routine to prevent or slow the development of muscle contractures and deformities. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management of Contractures&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Manage contractures by using orthotic devices, appropriate seating position in the wheelchair, and standing supports. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical intervention &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgical intervention should be considered for scoliosis when the Cobb angle is between 30&amp;deg; and 40&amp;deg;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Vitamins and Mineral Supplements&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Recommend vitamin D, calcium, and bisphosphonates, following the guidelines for other neuromuscular disorders. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment Recommendations for the Respiratory Element of Late-Onset Pompe Disease&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Involve a pulmonologist experienced in managing patients with neuromuscular diseases. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Up-to-date vaccinations, including vaccination against pneumococcus and influenza &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Early and aggressive treatment of bacterial and viral infections &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clear secretions from airways (e.g., cough assist device, suction) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Train/educate patients and families to use assisted cough and inspiratory muscle techniques. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treat sleep-disordered breathing with continuous positive airway pressure (CPAP) or bilevel nocturnal noninvasive ventilation (BiPAP). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;In the absence of sleep studies, consider BiPAP ventilation if arterial Pco&lt;sub&gt;2&lt;/sub&gt; is &amp;ge;45 mm Hg, supine forced vital capacity is &amp;lt;50% of predicted, negative inspiratory force is &amp;lt;60 cm H&lt;sub&gt;2&lt;/sub&gt;O, or oxygen saturation falls to &amp;lt;88% for 5 continuous minutes during sleep. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treat concomitant conditions, such as asthma or cardiomyopathy. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Consider enzyme replacement therapy. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment Recommendations for the Gastrointestinal Element of Late-Onset Pompe Disease&lt;/strong&gt;&lt;/span&gt; (Kishnani et al., 2006)&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Coordinate treatment through a multidisciplinary neuromuscular clinic. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Involve an experienced dietitian. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Obtain videofluoroscopic swallowing assessment and evaluation for gastroesophageal reflux to guide management of feeding either orally or through a feeding tube. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Monitor growth parameters carefully. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Provide adequate nutrition consisting of high protein diet (20% to 25%) with attention to vitamins and minerals. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Educate patients about the appropriate use of over-the-counter medications. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients receiving enzyme replacement therapy should be monitored for immunoglobulin G (IgG) antibodies every 3 months for 2 years and then annually thereafter. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Treatment Warning for Alglucosidase alfa (Lumizyme; Genzyme Corporation, Cambridge, Massachusetts)&lt;/span&gt;&lt;/strong&gt; (&quot;Lumizyme,&quot; 2010)&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;em&gt;Warning&lt;/em&gt;: Life-threatening anaphylactic reactions, severe allergic reactions, and immune-mediated reactions have been observed in some patients during Lumizyme infusions (van der Ploeg et al., 2010). Therefore, appropriate medical support should be readily available when Lumizyme is administered. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment Recommendations Based on the Stage and Severity of Pompe Disease&lt;/strong&gt;&lt;/span&gt; &lt;/p&gt;&#xD;&#xA;&lt;table border=&quot;1&quot; cellspacing=&quot;3&quot; cellpadding=&quot;5&quot; summary=&quot;Table: Treatment Recommendations Based on the Stage and Severity of Pompe Disease&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Condition&lt;/th&gt;&#xD;&#xA;            &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Recommendations&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Presymptomatic patients without objective signs&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;Patients should be examined every 6 months for proximal muscle weakness and pulmonary function . &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Enzyme replacement therapy (ERT) should be started at:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Onset of symptoms &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Onset of detectable proximal muscle weakness or reduced forced vital capacity in either upright or supine position &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Presymptomatic patients with objective signs&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;ERT should be started if:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Presymptomatic patients have proximal muscle weakness detectable on the Medical Research Council scale or reduced forced vital capacity in either upright or supine position &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Symptomatic patients&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;ERT should be started if:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;There is either reduction in forced vital capacity in either upright or supine position or increased limb weakness &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Patient has difficulty completing activities of daily living &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Is or is not using noninvasive ventilation &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Severe symptoms&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;If the patient is confined to a wheelchair and is using invasive ventilation during the day and at night:&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;ERT is recommended for 1 year, followed by evaluation of the effectiveness of therapy. &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;After one year, ERT is recommended on a case-by-case basis for patients who require continuous invasive ventilation, using the collective information acquired by the multispecialty team. &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Continue ERT if severe signs and symptoms are stabilized or improved. &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Length of ERT Monitoring&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;            &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                &lt;li&gt;One year followed by reassessment to consider whether to continue the treatment &lt;/li&gt;&#xD;&#xA;                &lt;li&gt;Patients receiving enzyme replacement therapy should be monitored for immunoglobulin G (IgG) antibodies every 3 months for 2 years, then annually thereafter. &lt;/li&gt;&#xD;&#xA;            &lt;/ul&gt;&#xD;&#xA;            &lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Treatment Recommendations Based on the Experience in Taiwan&lt;/strong&gt;&lt;/span&gt; (Chien et al., 2009)&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The authors recommend the implementation of newborn screening programs in all states to diagnose and properly treat infants with or at risk of developing infantile-onset or late-onset Pompe disease. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None provided&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="98" OrdBy="605" ID="425" Name="References Supporting the Recommendations" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Chien YH, Lee NC, Thurberg BL, Chiang SC, Zhang XK, Keutzer J, Huang AC, Wu MH, Huang PH, Tsai FJ, Chen YT, Hwu WL. Pompe disease in infants: improving the prognosis by newborn screening and early  treatment. Pediatrics. 2009 Dec;124(6):e1116-25. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=19948615&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE, Crowley JF, Downs S, Howell RR, Kravitz RM, Mackey J, Marsden D, Martins AM, Millington DS, Nicolino M, O'Grady G, Patterson MC, Rapoport DM, Slonim A, Spencer CT, Tifft CJ, Watson MS. Pompe disease diagnosis and management guideline. Genet Med. 2006 May;8(5):267-88. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=16702877&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Lumizyme [package insert]. Cambridge (MA): Genzyme Corporation; 2010. &lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ, Herson S, Kishnani PS, Laforet P, Lake SL, Lange DJ, Leshner RT, Mayhew JE, Morgan C, Nozaki K, Park DJ, Pestronk A, Rosenbloom B, Skrinar A, van Capelle CI, van der Beek NA, Wasserstein M, Zivkovic SA. A randomized study of alglucosidase alfa in late-onset Pompe's disease. N Engl J Med. 2010 Apr 15;362(15):1396-406. &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=20393176&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The recommendations are based on expert consensus.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Appropriate treatment of late-onset Pompe disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Life-threatening anaphylactic reactions, severe allergic reactions, and immune-mediated reactions have been observed in some patients during Lumizyme infusions. Therefore, appropriate medical support should be readily available when Lumizyme is administered. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Therapeutic exercise in late-onset Pompe disease may pose a risk for cardiopulmonary compromise in this population. Consequently, a pulmonologist should evaluate the patient before initiation of an exercise program. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Aggressive stretching should be approached cautiously because, at least in severely affected children, a tendency for pathologic fracture has been observed. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This article was prepared and reviewed by the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) and did not undergo the separate review process of Muscle &amp;amp; Nerve.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;An implementation strategy was not provided.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Cupler EJ, Berger KI, Leshner RT, Wolfe GI, Han JJ, Barohn RJ, Kissel JT, AANEM Consensus Committee on Late-onset Pompe Disease. Consensus treatment recommendations for late-onset Pompe disease. Muscle Nerve. 2012 Mar;45(3):319-33. [108 references] &lt;a href=&quot;http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=pubmed&amp;dopt=Abstract&amp;list_uids=22173792&quot; target=&quot;_blank&quot;&gt;PubMed&lt;/a&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2012 Mar" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="American Association of Neuromuscular and Electrodiagnostic Medicine - Medical Specialty Society" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This article was sponsored by an unrestricted grant from Genzyme Corporation.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Consensus Committee on Late-Onset Pompe Disease&lt;/p&gt;&#xD;&#xA;&lt;p&gt;AANEM Task Force&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: Edward J. Cupler, MD, Department of Neurology, Oregon Health &amp;amp; Science University, Portland, Oregon, USA; Kenneth I. Berger, MD, Division of Pulmonary and Critical Care Medicine, Department of Medicine and Department of Physiology and Neuroscience, New York University School of Medicine, New York, New York, USA; Robert T. Leshner, MD, Department of Neurosciences, University of California San Diego, San Diego, California, USA; Gil I. Wolfe, MD, Department of Neurology, University of Texas Southwestern Medical School, Dallas, Texas, USA; Jay J. Han, MD, Department of Physical Medicine and Rehabilitation, University of California Davis, Sacramento, California, USA; Richard J. Barohn, MD (&lt;em&gt;Co-chair&lt;/em&gt;), Department of Neurology, University of Kansas Medical Center, Kansas City, Kansas, USA; John T. Kissel, MD (&lt;em&gt;Co-chair&lt;/em&gt;), Department of Neurology, Division of Neuromuscular Medicine, Ohio State University, Columbus, Ohio, USA&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Task Force Co-chairs&lt;/em&gt;: Dr. Barohn has nothing to disclose. Dr. Kissel serves as a consultant for Alexion Pharmaceuticals for a clinical trial in myasthenia gravis.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Task Force Members&lt;/em&gt;: Dr. Han has nothing to disclose. Dr. Berger has served as a consultant to Genzyme Corporation for clinical trials in MPS I and Pompe disease, and he has served as a consultant to BioMarin Corporation for clinical trials in MPS IV and MPS VI. Dr. Cupler is a member of the speaker bureau for Genzyme Corporation and for Athena Diagnostics, Inc., and is a member of the Pompe Registry North American Board of Advisors for Genzyme Corporation. Dr. Leshner is a member of the Genzyme Global Advisory Board for Pompe disease and has received honoraria for speaking engagements and research support from Genzyme Corporation. Dr. Wolfe has served on the speaker bureau for Genzyme Corporation. None of the authors of this article is an inventor, and no authors are receiving royalty payments. All authors received travel support and honoraria for the initial consensus development meeting from MedLogix Communications, LLC, and the AANEM, through an educational grant from Genzyme Corporation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Dr. Barohn and Dr. Kissel were the co-chairs of the task force. They were chosen as chairs because they were free from any conflict. Every attempt was made to include authors without a conflict. Due to several physicians being unable to attend the initial meeting, the final panel involved three physicians without a conflict and four with a conflict (KIB, EJC, TRL, GIW).&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;http://www.aanem.org/getmedia/c2919434-f4ed-489c-9864-efb35b3b67d8/Pompe-Position-Statement.pdf.aspx&quot; title=&quot;American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Web site&quot;&gt;American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI Institute on September 14, 2012. The information was verified by the guideline developer on October 29, 2012.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This document is provided as an educational service by the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM). It was developed by members of the AANEM and approved by the AANEM Board of Directors. For further information, visit the &lt;a href=&quot;http://www.aanem.org/Home.aspx&quot; title=&quot;AANEM Web site&quot;&gt;AANEM Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
